跳至主要内容
临床试验/CTRI/2020/08/027068
CTRI/2020/08/027068尚未招募2 期

A Randomized Phase II Trial Comparing perioperative Single dose Intravesical Gemcitabine versus Mitomycin-C Following Complete Resection of Non Muscle Invasive Bladder Cancer: Evaluation of Efficacy and Tolerance

AIIMS0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方
AIIMS

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • a) Age 18 or above
  • b) Lesion suspicious for Non-muscle invasive bladder cancer after complete TURBT
  • c) General condition of the patient sufficient for 1 yr or more of follow-up (according to the attending physician)

排除标准

  • a) Any prior non-urothelial or muscle-invasive bladder cancer
  • b)History of any prior intravesical therapy for non muscle invasive bladder cancer in last
  • c) Intraoperative evidence of tumor in urethra or ureter
  • d)Suspicion of muscle invasion after complete resection
  • e)Previous pelvic radiotherapy for any malignancy.
  • f)Prior treatment for any malignancy within 5 years (other than nonâ??muscle-invasive
  • bladder urothelial cancer).
  • g)Significant renal dysfunction (S. Cr >2)
  • h)Hepatic dysfunction
  • i)Poor performance status

研究者

发起方
AIIMS

相似试验